Frontiers in Bioengineering and Biotechnology (Dec 2022)
Exosomes in pathogenesis, diagnosis, and therapy of ischemic stroke
- Meiqi Jin,
- Meiqi Jin,
- Meiqi Jin,
- Meiqi Jin,
- Shuxia Zhang,
- Shuxia Zhang,
- Shuxia Zhang,
- Shuxia Zhang,
- Mengchen Wang,
- Mengchen Wang,
- Mengchen Wang,
- Mengchen Wang,
- Qiaoyu Li,
- Qiaoyu Li,
- Qiaoyu Li,
- Qiaoyu Li,
- Jiahui Ren,
- Jiahui Ren,
- Jiahui Ren,
- Yun Luo,
- Yun Luo,
- Yun Luo,
- Yun Luo,
- Xiaobo Sun,
- Xiaobo Sun,
- Xiaobo Sun,
- Xiaobo Sun
Affiliations
- Meiqi Jin
- Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China
- Meiqi Jin
- Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, China
- Meiqi Jin
- Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
- Meiqi Jin
- NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing, China
- Shuxia Zhang
- Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China
- Shuxia Zhang
- Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, China
- Shuxia Zhang
- Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
- Shuxia Zhang
- NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing, China
- Mengchen Wang
- Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China
- Mengchen Wang
- Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, China
- Mengchen Wang
- Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
- Mengchen Wang
- NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing, China
- Qiaoyu Li
- Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China
- Qiaoyu Li
- Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, China
- Qiaoyu Li
- Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
- Qiaoyu Li
- NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing, China
- Jiahui Ren
- Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China
- Jiahui Ren
- Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, China
- Jiahui Ren
- Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
- Yun Luo
- Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China
- Yun Luo
- Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, China
- Yun Luo
- Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
- Yun Luo
- NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing, China
- Xiaobo Sun
- Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China
- Xiaobo Sun
- Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, China
- Xiaobo Sun
- Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
- Xiaobo Sun
- NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing, China
- DOI
- https://doi.org/10.3389/fbioe.2022.980548
- Journal volume & issue
-
Vol. 10
Abstract
Ischemic stroke is one of the major contributors to death and disability worldwide. Thus, there is an urgent need to develop early brain tissue perfusion therapies following acute stroke and to enhance functional recovery in stroke survivors. The morbidity, therapy, and recovery processes are highly orchestrated interactions involving the brain with other tissues. Exosomes are natural and ideal mediators of intercellular information transfer and recognized as biomarkers for disease diagnosis and prognosis. Changes in exosome contents express throughout the physiological process. Accumulating evidence demonstrates the use of exosomes in exploring unknown cellular and molecular mechanisms of intercellular communication and organ homeostasis and indicates their potential role in ischemic stroke. Inspired by the unique properties of exosomes, this review focuses on the communication, diagnosis, and therapeutic role of various derived exosomes, and their development and challenges for the treatment of cerebral ischemic stroke.
Keywords
